Article source：
May 22,2026
View：
455 Recently, GB10 Injection, an ophthalmology innovative drug independently developed by Shenzhen Kexing Pharmaceutical Co., Ltd. (a wholly owned subsidiary of Kexing Biopharm), has completed dosing of the first subject in its Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD). This marks a continued acceleration in the company’s innovative drug development pipeline.
The GB10 project is a self-developed ophthalmic high-concentration biologic formulation with global intellectual property rights. It is an anti-VEGF/Ang-2 bispecific antibody fusion protein drug designed specifically for ocular use.
GB10 Injection has a concentration of 140 mg/mL, which enables either reduced injection volume or increased dosing capacity, and is expected to extend the dosing interval to once every four months. This may significantly improve patient compliance by reducing injection frequency.
Preclinical data demonstrate that GB10’s biological activity and in vivo efficacy are comparable to international benchmark products. In a laser-induced monkey CNV (choroidal neovascularization) model, GB10 effectively inhibited pathological ocular neovascularization in the fundus.
Neovascular age-related macular degeneration (nAMD) is one of the leading causes of blindness in people over 50 worldwide. With the rapid development of the internet, increased screen time from mobile devices, and accelerating population aging, demand for ophthalmic therapies continues to grow.
Long-acting treatment regimens that extend dosing intervals are increasingly important in addressing clinical challenges such as frequent injections and low patient adherence.
According to data from Huajing Industrial Research Institute, the global market for drugs treating retinal neovascular diseases reached approximately USD 15.6 billion in 2024, while the corresponding market in China reached approximately RMB 5 billion.
Kexing Biopharm is accelerating the development of its internally developed dual-target antibody ophthalmic pipeline while actively introducing external ophthalmic products for global commercialization, including aflibercept biosimilars and olopatadine hydrochloride eye drops.
Through continuous innovation and portfolio expansion, the company is strengthening its international presence and accelerating its globalization strategy.
Looking ahead, Kexing Biopharm will uphold its philosophy of “precision manufacturing, precision medication, and safeguarding health,” providing patients worldwide with more high-quality and accessible treatment options.
BACK TO LIST
May 31,2026
